Tg Therapeutics (TGTX) Change in Receivables (2021 - 2026)

Tg Therapeutics' Change in Receivables history runs 6 years deep, the most recent figure standing at $86.4 million for Q1 2026.

• In Q1 2026, Change in Receivables rose 41.82% year-over-year to $86.4 million; the TTM figure through Mar 2026 stood at $201.9 million (up 61.36% YoY), while the FY2025 annual figure was $176.4 million, up 125.94% from the prior year.
• Change in Receivables was $86.4 million for Q1 2026 at Tg Therapeutics, up from $40.2 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $86.4 million in Q1 2026 to a low of -$814000.0 in Q2 2022.
• Historically, Change in Receivables has averaged $24.4 million across 5 years, with a median of $16.3 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Change in Receivables tumbled 608.75% in 2022, then soared 24913.64% in 2023.
• A 5-year view of Change in Receivables shows it stood at -$88000.0 in 2022, then surged by 13478.41% to $11.8 million in 2023, then climbed by 14.31% to $13.5 million in 2024, then soared by 199.03% to $40.2 million in 2025, then jumped by 114.74% to $86.4 million in 2026.
• The last three Change in Receivables figures came in at $86.4 million (Q1 2026), $40.2 million (Q4 2025), and $33.9 million (Q3 2025), per Business Quant data.